S&P 500   3,941.26
DOW   33,596.34
QQQ   281.68
Franchising Could Be the Secret to Reaping the Rewards of a Down Economy. Here Are 5 Reasons Why.
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Splunk is Suddenly Looking Like a Slam Dunk
Can GlobalFoundries Be the U.S. Version of Taiwan Semi ?
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
3 Big Box Retail Bets for the Holidays
How Long Does it Take to Become a Profitable Trader?
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Biden visits Arizona computer chip site, highlights jobs
Trump Org. jury seeks clarity as deliberations continue
S&P 500   3,941.26
DOW   33,596.34
QQQ   281.68
Franchising Could Be the Secret to Reaping the Rewards of a Down Economy. Here Are 5 Reasons Why.
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Splunk is Suddenly Looking Like a Slam Dunk
Can GlobalFoundries Be the U.S. Version of Taiwan Semi ?
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
3 Big Box Retail Bets for the Holidays
How Long Does it Take to Become a Profitable Trader?
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Biden visits Arizona computer chip site, highlights jobs
Trump Org. jury seeks clarity as deliberations continue
S&P 500   3,941.26
DOW   33,596.34
QQQ   281.68
Franchising Could Be the Secret to Reaping the Rewards of a Down Economy. Here Are 5 Reasons Why.
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Splunk is Suddenly Looking Like a Slam Dunk
Can GlobalFoundries Be the U.S. Version of Taiwan Semi ?
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
3 Big Box Retail Bets for the Holidays
How Long Does it Take to Become a Profitable Trader?
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Biden visits Arizona computer chip site, highlights jobs
Trump Org. jury seeks clarity as deliberations continue
S&P 500   3,941.26
DOW   33,596.34
QQQ   281.68
Franchising Could Be the Secret to Reaping the Rewards of a Down Economy. Here Are 5 Reasons Why.
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Splunk is Suddenly Looking Like a Slam Dunk
Can GlobalFoundries Be the U.S. Version of Taiwan Semi ?
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
3 Big Box Retail Bets for the Holidays
How Long Does it Take to Become a Profitable Trader?
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Biden visits Arizona computer chip site, highlights jobs
Trump Org. jury seeks clarity as deliberations continue
NASDAQ:REPL

Replimune Group - REPL Stock Forecast, Price & News

$18.89
-1.06 (-5.31%)
(As of 12/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$18.74
$19.99
50-Day Range
$16.62
$21.00
52-Week Range
$13.05
$30.89
Volume
427,446 shs
Average Volume
307,341 shs
Market Capitalization
$939.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.00

Replimune Group MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
122.3% Upside
$42.00 Price Target
Short Interest
Healthy
5.66% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.28
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.02) to ($3.43) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

408th out of 1,023 stocks

Biological Products, Except Diagnostic Industry

65th out of 170 stocks

REPL stock logo

About Replimune Group (NASDAQ:REPL) Stock

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Receive REPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter.

REPL Stock News Headlines

Expert Ratings for Replimune Group
Replimune: Recent Developments Strengthen Bull Thesis
Is Replimune Group (NASDAQ:REPL) Using Too Much Debt?
Replimune Group, Inc. (REPL)
Analyst Ratings for Replimune Group
Replimune Group: Q3 Earnings Insights
See More Headlines
Receive REPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter.

REPL Company Calendar

Last Earnings
11/04/2021
Today
12/06/2022
Next Earnings (Estimated)
2/02/2023
Fiscal Year End
3/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:REPL
Fax
N/A
Employees
152
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$42.00
High Stock Price Forecast
$52.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+122.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-118,040,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$8.71 per share

Miscellaneous

Free Float
37,901,000
Market Cap
$939.57 million
Optionable
Not Optionable
Beta
1.86

Key Executives

  • Mr. Philip Astley-Sparke FSA (Age 51)
    CEO & Director
    Comp: $880.5k
  • Dr. Robert Coffin Ph.D. (Age 57)
    Founder, Pres, Chief R&D Officer and Director
    Comp: $785.89k
  • Ms. Tanya N. Lewis M.S. (Age 51)
    Chief Devel. Operations Officer
    Comp: $4.7k
  • Mr. Sushil Patel Ph.D. (Age 51)
    Chief Commercial Officer
    Comp: $594.58k
  • Ms. Jean M. Franchi (Age 56)
    Principal Accounting Officer, CFO, Treasurer, Sec. & Compliance Officer
  • Dr. Colin A. Love Ph.D. (Age 64)
    Chief Operating Officer
  • Dr. Pamela Esposito Ph.D. (Age 47)
    Chief Bus. Officer













REPL Stock - Frequently Asked Questions

Should I buy or sell Replimune Group stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" REPL shares.
View REPL analyst ratings
or view top-rated stocks.

What is Replimune Group's stock price forecast for 2023?

6 equities research analysts have issued 1 year price targets for Replimune Group's stock. Their REPL share price forecasts range from $30.00 to $52.00. On average, they anticipate the company's stock price to reach $42.00 in the next twelve months. This suggests a possible upside of 122.3% from the stock's current price.
View analysts price targets for REPL
or view top-rated stocks among Wall Street analysts.

How have REPL shares performed in 2022?

Replimune Group's stock was trading at $27.10 at the start of the year. Since then, REPL stock has decreased by 30.3% and is now trading at $18.89.
View the best growth stocks for 2022 here
.

When is Replimune Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 2nd 2023.
View our REPL earnings forecast
.

How were Replimune Group's earnings last quarter?

Replimune Group, Inc. (NASDAQ:REPL) announced its quarterly earnings data on Thursday, November, 4th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by $0.05.

What other stocks do shareholders of Replimune Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), Peabody Energy (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC).

When did Replimune Group IPO?

(REPL) raised $100 million in an IPO on Friday, July 20th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

What is Replimune Group's stock symbol?

Replimune Group trades on the NASDAQ under the ticker symbol "REPL."

Who are Replimune Group's major shareholders?

Replimune Group's stock is owned by many different institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (8.39%), Atlas Venture Life Science Advisors LLC (6.25%), BlackRock Inc. (5.56%), Vanguard Group Inc. (3.72%), State Street Corp (2.92%) and Emerald Advisers LLC (2.31%). Insiders that own company stock include Colin Love, Fund Iv LP Omega, Jason P Rhodes, Jean M Franchi, Pamela Esposito, Philip Astley-Sparke and Robert Coffin.
View institutional ownership trends
.

How do I buy shares of Replimune Group?

Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Replimune Group's stock price today?

One share of REPL stock can currently be purchased for approximately $18.89.

How much money does Replimune Group make?

Replimune Group (NASDAQ:REPL) has a market capitalization of $939.57 million. The company earns $-118,040,000.00 in net income (profit) each year or ($2.74) on an earnings per share basis.

How many employees does Replimune Group have?

The company employs 152 workers across the globe.

How can I contact Replimune Group?

Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The official website for the company is www.replimune.com. The company can be reached via phone at (781) 222-9600 or via email at ir@replimune.com.

This page (NASDAQ:REPL) was last updated on 12/7/2022 by MarketBeat.com Staff